Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.14, read 2026-10-25
Ethical does not pass the values gate
Price17.82 USD
Fair value11.19
Our investment reviews on this name
2026-10-02Read Accumulation14.46+23.2% to today ✓Markup gives way to Accumulation after a 56% rise in 13 weeks
2026-07-02Read Markup9.25+92.6% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
PagerDuty, Inc. holds its Accumulation at $17.82. The statistical read favours the sellers, held for 40 days.
As held on the ledger · 2026-10-26
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 40 days
Price at the screen
$17.82
Valuation
7.73 trailing · 10.48 forward price to earnings
Values screen
FAIL
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
75.00%
Below 33%
Interest-bearing debt is 75.0% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
85.25%
Below 33%
Interest-bearing cash and securities are 85.3% of assets, above the one-third limit.
Fail
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
4.61%
Below 5%
Only 4.6% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
PagerDuty,'s business is in a permissible area, but its interest-bearing debt is about 75% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when PD's ethical verdict changes
Today PD does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-26 screen. The gold marker is the market price at the same screen. The price runs 32.7% above the base estimate.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-26 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PD trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-26Accumulation$16.64+0.0%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 45%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (7 analysts) rates it buy, with a mean price target of $8. Insiders have been net sellers over the past quarter. Since the last review it its composite score eased.
2026-10-19Accumulation$16.64+15.1%Entry 7
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 15.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 45%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (7 analysts) rates it buy, with a mean price target of $8. Insiders have been net sellers over the past quarter.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 56.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 45%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (7 analysts) rates it buy, with a mean price target of $8. Insiders have been net sellers over the past quarter. Since the last review it dropped out of the Tech 100; its composite score eased.
2026-09-09Markup$9.25+0.0%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 45%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (7 analysts) rates it buy, with a mean price target of $8.
2026-08-08Markup$9.25+0.0%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 45%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (7 analysts) rates it buy, with a mean price target of $8.
2026-07-18Markup$9.25+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 45%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (7 analysts) rates it buy, with a mean price target of $8.
2026-07-03Markup$9.25+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$9.25Entry 1
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.